Melissa Baird Sells 17,625 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) COO Melissa Baird sold 17,625 shares of Hims & Hers Health stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $20.42, for a total value of $359,902.50. Following the completion of the transaction, the chief operating officer now owns 541,432 shares of the company’s stock, valued at approximately $11,056,041.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Melissa Baird also recently made the following trade(s):

  • On Thursday, May 2nd, Melissa Baird sold 11,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $12.08, for a total transaction of $141,940.00.
  • On Monday, April 8th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.74, for a total transaction of $173,209.74.
  • On Friday, April 5th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.58, for a total transaction of $171,329.58.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $21.57 on Friday. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $21.75. The stock has a market cap of $4.63 billion, a price-to-earnings ratio of -2,157.00 and a beta of 1.08. The firm has a fifty day moving average of $14.87 and a 200-day moving average of $11.92.

Hims & Hers Health (NYSE:HIMSGet Free Report) last issued its earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million during the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. Hims & Hers Health’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.05) EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.18 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on HIMS. Citigroup downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their target price for the company from $16.00 to $20.00 in a research note on Wednesday, May 22nd. SVB Leerink began coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They issued a “market perform” rating and a $10.00 target price for the company. Leerink Partnrs reaffirmed a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. Piper Sandler lifted their price target on shares of Hims & Hers Health from $11.00 to $13.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 7th. Finally, Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, May 22nd. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.14.

Check Out Our Latest Stock Analysis on HIMS

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Belpointe Asset Management LLC grew its stake in Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after buying an additional 1,205 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Hims & Hers Health by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after acquiring an additional 1,561 shares during the last quarter. Pathstone Family Office LLC grew its position in Hims & Hers Health by 2.8% during the 3rd quarter. Pathstone Family Office LLC now owns 65,876 shares of the company’s stock worth $414,000 after acquiring an additional 1,824 shares during the last quarter. Swiss National Bank increased its holdings in Hims & Hers Health by 0.7% during the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after purchasing an additional 2,000 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in Hims & Hers Health by 10.0% in the 1st quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock valued at $344,000 after purchasing an additional 2,023 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Further Reading

Insider Buying and Selling by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.